Results 1 to 10 of about 38,540 (306)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Frontiers in Immunology, 2022
Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei, Yueyao Yang, Gang Wang, Ming Liu   +3 more
doaj   +1 more source

Modelling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion [PDF]

, 2016
We have developed a mathematical framework for describing a bispecific monoclonal antibody interaction with two independent membrane-bound targets that are expressed on the same cell surface.
Argungu, Maryam, Hadji, Aymen, Hawkins, Emma, McGinty, Sean, Nouri, Fatma Z., Sengers, Bram G., Sepp, Armin, Taylor, Adam, Weber, Andrew   +8 more
core   +1 more source

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

Molecular Therapy: Oncolytics, 2019
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes.
Jiayu Liu, Xiaoqiong Wu, Limin Lin, Haitao Pan, Yanlan Wang, Yumei Li, Yining Zhao, Zhong Wang   +7 more
doaj   +1 more source

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy [PDF]

, 2016
Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them.
Basilico, Cristina, Blanchetot, Christophe, de Haard, Hans, De Jonge, Natalie, El Khattabi, Mohamed, Godar, Marie, Hanssens, Valérie, Hultberg, Anna, Lambrecht, Bart, Michieli, Paolo, Morello, Virginia, Sadi, Ava, Saunders, Michael   +12 more
core   +2 more sources

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

Frontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte   +27 more
doaj   +1 more source

Antibody engineering for increased potency, breadth and half-life [PDF]

, 2015
Purpose of review: This review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies.
Bjorkman, Pamela J., Scharf, Louise, Sievers, Stuart A., West, Anthony P., Jr.   +3 more
core   +1 more source

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng   +3 more
doaj   +1 more source

Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices

Nature Communications, 2020
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl, Klaus Mayer, Felix Bormann, Harald Duerr, Eike Hoffmann, Bianca Nussbaum, Michael Tischler, Martina Wagner, Andreas Kuglstatter, Lea Leibrock, Can Buldun, Guy Georges, Ulrich Brinkmann   +12 more
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia, Curnock, Adam, De Strooper, Bart, Dewilde, Maarten, Hassanzadeh-Ghassabeh, Gholamreza, Haustraete, Jurgen, Joyce, Peter, Lemmens, Robin, Little, Susan, Robberecht, Wim, Roucourt, Bart, Rue, Laura, Schoonaert, Lies, Timmers, Mieke, Van Damme, Philip, Van den Bosch, Ludo, Weber, Peter   +16 more
core   +2 more sources

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

STAR Protocols, 2022
Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li, Alexander C. Partin, Liangjun Zhao, Irwin Chen, Mark L. Michaels, Zhulun Wang, Fernando Garces, Danyang Gong, Timothy P. Riley   +8 more
doaj   +1 more source